A new pooled analysis of prospective cohort data identifies three critical takeaways regarding coffee consumption and colorectal cancer outcomes. First, the magnitude of potential benefit is modest but consistent: each additional daily cup was associated with approximately 4% mortality reduction across 5,442 patients. Second, the apparent protective effect operates independently of caffeine content—both caffeinated and decaffeinated coffee showed equivalent associations, indicating that polyphenols and other bioactive compounds likely mediate the benefit rather than stimulant properties.
Third, and importantly, this remains observational evidence. While the pooled analysis demonstrates an epidemiological association, causation remains unproven, and unmeasured confounding cannot be excluded. Colorectal cancer patients considering dietary modifications should recognize that randomized controlled trials and mechanistic studies are needed to establish whether coffee consumption directly influences survival or merely correlates with other protective behaviors and characteristics. Patients should consult their oncology team before making significant dietary changes.
Read the full article on GMJ Newsroom.
Was this article helpful?
